Kura Oncology (KURA) financial statements
Kura Oncology reported revenue of $67M in fiscal 2025, up 25.2% a year over 1 years.
Net income was -$279M.
Free cash flow was -$71M.
The diluted share count rose 369% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Kura Oncology's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0 | $54M | $67M |
| Research and development | — | $26M | $47M | $48M | $60M | $85M | $93M | $115M | $170M | $251M |
| Selling, general and admin | — | $10M | $16M | $20M | $32M | $47M | $47M | $51M | $77M | $120M |
| Operating income | — | — | — | — | — | — | -$140M | -$166M | -$193M | -$304M |
| Interest expense | $577,000 | $888,000 | $970,000 | $580,000 | $578,000 | $414,000 | $229,000 | $2M | $2M | $2M |
| Pre-tax income | — | — | — | — | — | — | -$136M | -$153M | -$172M | -$278M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2M | $297,000 |
| Net income | -$28M | -$35M | -$60M | -$63M | -$90M | -$130M | -$136M | -$153M | -$174M | -$279M |
| EPS (diluted) | -$1.47 | -$1.52 | -$1.72 | -$1.51 | -$1.69 | -$1.97 | -$2.03 | -$2.08 | -$2.02 | -$3.18 |
| Diluted shares | 19M | 23M | 35M | 42M | 53M | 66M | 67M | 73M | 86M | 88M |
| Operating margin | — | — | — | — | — | — | — | — | -358.5% | -449.9% |
| Net margin | — | — | — | — | — | — | — | — | -322.9% | -412.9% |
Balance sheet
Fiscal years, from Kura Oncology's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $68M | $93M | $179M | $237M | $633M | $518M | $438M | $424M | $727M | $667M |
| Receivables | — | — | — | — | — | — | — | — | $2M | $9M |
| Inventory | — | — | — | — | — | — | — | — | $0 | $413,000 |
| Total current assets | $69M | $95M | $181M | $240M | $637M | $522M | $446M | $432M | $745M | $709M |
| Property, plant and equipment | $40,000 | $10,000 | — | $44,000 | $2M | $3M | $3M | $2M | $2M | $8M |
| Total assets | $70M | $96M | $182M | $242M | $647M | $534M | $456M | $449M | $760M | $738M |
| Total current liabilities | $5M | $10M | $14M | $16M | $26M | $22M | $24M | $35M | $79M | $117M |
| Long-term debt | $7M | $6M | $8M | $7M | $4M | — | $9M | $9M | $7M | $10M |
| Total liabilities | $13M | $16M | $21M | $23M | $36M | $27M | $36M | $52M | $347M | $564M |
| Shareholders' equity | $57M | $80M | $161M | $219M | $611M | $507M | $420M | $397M | $414M | $174M |
| Net debt | -$2M | -$4M | -$9M | -$19M | -$318M | -$91M | -$43M | -$28M | -$215M | -$139M |
Cash flow
Fiscal years, from Kura Oncology's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25M | -$28M | -$49M | -$55M | -$70M | -$105M | -$110M | -$125M | $134M | -$64M |
| Capital spending | — | — | — | — | $2M | $1M | $626,000 | $168,000 | $472,000 | $7M |
| Free cash flow | — | — | — | — | -$72M | -$106M | -$111M | -$125M | $134M | -$71M |
| Stock-based compensation | $2M | $5M | $9M | $9M | $13M | $24M | $26M | $28M | $34M | $37M |
| Net borrowing | $7M | — | -$623,000 | — | -$250,000 | -$7M | $10M | — | — | — |
| Free cash flow margin | — | — | — | — | — | — | — | — | 248.4% | -104.8% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for KURA.
Open KURA in InvestinglyQuestions
What was Kura Oncology's revenue in 2025?
$67M in fiscal 2025, from its 10-K filing.
How much free cash flow does Kura Oncology generate?
-$71M in fiscal 2025 (operating cash flow minus capital spending).
From Kura Oncology's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.